July 2026
Serotonin
What July 2026's 23 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 23 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research on serotonin in July 2026 focused on the mechanisms and therapeutic potential of psychedelics, particularly psilocybin, which was shown to act through 5-HT2A receptors to induce dendritic signaling and plasticity in a brain-state- and sex-dependent manner. Reviews and preclinical studies consistently supported psilocybin's promise for depression and other conditions, but evidence for direct clinical efficacy remained preliminary, with safety concerns and long-term effects still requiring further investigation.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors 2026 | experimental study | Supports | Psilocybin transiently increased dendritic calcium event rates in apical tufts in a brain state- and 5-HT2A receptor-dependent manner, and altered the predictive relationship between acute dendritic calcium signaling and subsequent spine formation. | |
| Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia 2026 | experimental study using knockout mouse model | Mixed | Disrupted mGlu5 signaling amplified acute responses to psilocybin and revealed a sex-dependent long-term effect on sensorimotor gating, with female knockout mice showing sustained normalization in prepulse inhibition nine days after treatment. | |
| Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression 2026 | review | Supports | Ketamine and esketamine have the strongest evidence among rapid-acting antidepressant interventions for treatment-resistant depression, while psilocybin-assisted therapy shows promise but remains investigational. | |
| Integrated 5-HT2A-TrkB and G protein signaling in serotonergic psychedelic responses. 2026 | in vitro study | Supports | Serotonergic psychedelics recruit an integrated 5-HT2A-TrkB signaling network with distinct structural, transcriptional, and metabolic outputs, and TrkB silencing abolished dendritogenic responses. | |
| Sex-dependent effects of psychedelics: review of evidence from rodent models 2026 | review | Supports | Sex is a critical biological variable shaping the neural, physiological, and behavioral effects of classic psychedelics in rodents, with females often showing stronger or qualitatively distinct responses. | |
| Comprehensive in vitro profiling of traditional and emerging stimulants at monoamine transporters and the 5-HT2A receptor. 2026 | in vitro study | Supports | Most synthetic cathinones inhibited DAT at nanomolar concentrations, with N-pyrrolidine cathinones with methylenedioxy groups showing the highest DAT potency, suggesting high abuse potential based on DAT/SERT selectivity. | |
| Antidepressant effect of psychedelic compounds and mechanisms underlying the G protein-coupled receptors activation psychedelics: Antidepressant action and GPCR signaling. 2026 | review | Supports | Psychedelics, predominantly through 5-HT2A receptor activation and downstream signaling cascades, produce rapid and sustained antidepressant effects by promoting neuroplasticity and remodeling neural circuits. | |
| Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms 2026 | review | Supports | Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds, and structured 5-MeO-DMT treatment regimens for depression, indicating a convergence toward scalable and safer neuropsychiatric therapies. | |
| Psychedelic-Assisted Psychosexual Therapy 2026 | review | Supports | Proposes that classic serotonergic psychedelics, empathogenic-entactogenic agents, and glutamatergic dissociatives can enable direct engagement with traumatic, shame-laden, and affective antecedents of sexual difficulties by transiently altering states of consciousness and softening defensive avoidance. | |
| Study 35070 | in vitro experimental study | Supports | Brief 24-hour DMT exposure increases proliferation of human neural stem cells in a concentration-dependent manner and upregulates neurotrophin expression, including BDNF. | |
| Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol. 2026 | scoping review | Supports | Psilocybin shows potential as an alternative pharmacological strategy for OCD, especially for treatment-resistant patients, but systematic evidence mapping is needed. | |
| Psychedelics and the thalamocortical system: A scoping review 2026 | scoping review | Supports | Psychedelics affect thalamocortical connectivity, which may be important for clinical practice and understanding psychedelic neurobiology. | |
| Convergent increases in serotonin 1B receptor binding following ketamine and electroconvulsive therapy: a multi-centre bayesian re-analysis of PET data 2026 | observational cohort with re-analysis of multi-centre PET data | 42 | Supports | Large increases in 5-HT1BR binding were observed following both ketamine (6.4%) and ECT (9.3%), with changes distinguishable from placebo, but not associated with individual symptom improvement. |
| α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice. 2026 | preclinical experimental study | Mixed | Activation of the noradrenergic alpha-2 receptor suppresses serotonin 2A receptor-mediated head-twitch responses without blocking antidepressant-like effects in mice. | |
| What are the risks of serotonin syndrome when using MDMA and SSRIs together? 2026 | review | Supports | Combined use of MDMA and SSRIs may increase the risk of serotonin syndrome. | |
| Psilocibin: Current Evidence, Safety Signals, and Challenges in Assessing Potential Multi-Organ Effects 2026 | narrative review | Mixed | Current evidence does not confirm clinically meaningful intrinsic multi-organ toxicity of psilocybin under controlled conditions, but potential safety signals warrant further systematic evaluation. | |
| Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case Review 2026 | review | Supports | Psilocybin from Psilocybe cubensis mushrooms shows therapeutic potential for depression with sustainable symptom relief and fewer side effects than conventional treatments. | |
| Novel 6,5-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches 2026 | theoretical | Supports | Argues that novel 6,5-bicyclic compounds as 5-HT2A receptor agonists can be used in treating depression, anxiety, substance abuse, and headaches. | |
| Ligand-specific effects of 5-HT2A receptor antagonists on fear extinction in C57BL/6J mice: Comparative insights from MDL 11,939 and MDL 100,907 2026 | experimental study | Mixed | Repeated administration of the mixed 5-HT2A/2C antagonist MDL 11,939 impaired fear extinction in mice, while the selective 5-HT2A antagonist MDL 100,907 and the selective 5-HT2C antagonist SB 242084 did not significantly alter extinction learning. | |
| 5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation. 2026 | experimental study | Supports | 4-AcO-DMT suppresses innate fear responses in rats by activating 5-HT₂A receptors, which engage VIP interneurons in the prelimbic cortex. | |
| MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics. 2026 | computational study | Supports | The 5-HT2A receptor complexes with serotonin, psilocybin/psilocin, LSD, and lumateperone show total interaction energies from -35.38 to -71.98 kcal/mol, with Asp155, Phe339, Leu229, and Val366 being the main stabilizing residues. | |
| Single Ayahuasca administration attenuates alcohol relapse and associated behavioral, neurochemical, and oxidative alterations in rats 2026 | preclinical study | Supports | A single Ayahuasca administration reduced relapse-like ethanol intake, attenuated anxiety- and depressive-like behaviors, and partially reversed alcohol-induced changes in dopamine, serotonin, BDNF, and oxidative stress markers in a sex- and region-dependent manner. | |
| Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review. 2026 | systematic review | 20 | Mixed | Psychedelic drugs may modulate processes relevant to social cognition in psychiatric disorders, but direct evidence of improved social-cognitive functioning remains limited. |
Psilocybin transiently increased dendritic calcium event rates in apical tufts in a brain state- and 5-HT2A receptor-dependent manner, and altered the predictive relationship between acute dendritic calcium signaling and subsequent spine formation.
experimental study
Disrupted mGlu5 signaling amplified acute responses to psilocybin and revealed a sex-dependent long-term effect on sensorimotor gating, with female knockout mice showing sustained normalization in prepulse inhibition nine days after treatment.
experimental study using knockout mouse model
Ketamine and esketamine have the strongest evidence among rapid-acting antidepressant interventions for treatment-resistant depression, while psilocybin-assisted therapy shows promise but remains investigational.
review
Serotonergic psychedelics recruit an integrated 5-HT2A-TrkB signaling network with distinct structural, transcriptional, and metabolic outputs, and TrkB silencing abolished dendritogenic responses.
in vitro study
Sex is a critical biological variable shaping the neural, physiological, and behavioral effects of classic psychedelics in rodents, with females often showing stronger or qualitatively distinct responses.
review
Most synthetic cathinones inhibited DAT at nanomolar concentrations, with N-pyrrolidine cathinones with methylenedioxy groups showing the highest DAT potency, suggesting high abuse potential based on DAT/SERT selectivity.
in vitro study
Psychedelics, predominantly through 5-HT2A receptor activation and downstream signaling cascades, produce rapid and sustained antidepressant effects by promoting neuroplasticity and remodeling neural circuits.
review
Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds, and structured 5-MeO-DMT treatment regimens for depression, indicating a convergence toward scalable and safer neuropsychiatric therapies.
review
Proposes that classic serotonergic psychedelics, empathogenic-entactogenic agents, and glutamatergic dissociatives can enable direct engagement with traumatic, shame-laden, and affective antecedents of sexual difficulties by transiently altering states of consciousness and softening defensive avoidance.
review
Brief 24-hour DMT exposure increases proliferation of human neural stem cells in a concentration-dependent manner and upregulates neurotrophin expression, including BDNF.
in vitro experimental study
Psilocybin shows potential as an alternative pharmacological strategy for OCD, especially for treatment-resistant patients, but systematic evidence mapping is needed.
scoping review
Psychedelics affect thalamocortical connectivity, which may be important for clinical practice and understanding psychedelic neurobiology.
scoping review
Large increases in 5-HT1BR binding were observed following both ketamine (6.4%) and ECT (9.3%), with changes distinguishable from placebo, but not associated with individual symptom improvement.
observational cohort with re-analysis of multi-centre PET data Sample size: 42
Activation of the noradrenergic alpha-2 receptor suppresses serotonin 2A receptor-mediated head-twitch responses without blocking antidepressant-like effects in mice.
preclinical experimental study
Combined use of MDMA and SSRIs may increase the risk of serotonin syndrome.
review
Current evidence does not confirm clinically meaningful intrinsic multi-organ toxicity of psilocybin under controlled conditions, but potential safety signals warrant further systematic evaluation.
narrative review
Psilocybin from Psilocybe cubensis mushrooms shows therapeutic potential for depression with sustainable symptom relief and fewer side effects than conventional treatments.
review
Argues that novel 6,5-bicyclic compounds as 5-HT2A receptor agonists can be used in treating depression, anxiety, substance abuse, and headaches.
theoretical
Repeated administration of the mixed 5-HT2A/2C antagonist MDL 11,939 impaired fear extinction in mice, while the selective 5-HT2A antagonist MDL 100,907 and the selective 5-HT2C antagonist SB 242084 did not significantly alter extinction learning.
experimental study
4-AcO-DMT suppresses innate fear responses in rats by activating 5-HT₂A receptors, which engage VIP interneurons in the prelimbic cortex.
experimental study
The 5-HT2A receptor complexes with serotonin, psilocybin/psilocin, LSD, and lumateperone show total interaction energies from -35.38 to -71.98 kcal/mol, with Asp155, Phe339, Leu229, and Val366 being the main stabilizing residues.
computational study
A single Ayahuasca administration reduced relapse-like ethanol intake, attenuated anxiety- and depressive-like behaviors, and partially reversed alcohol-induced changes in dopamine, serotonin, BDNF, and oxidative stress markers in a sex- and region-dependent manner.
preclinical study
Psychedelic drugs may modulate processes relevant to social cognition in psychiatric disorders, but direct evidence of improved social-cognitive functioning remains limited.
systematic review Sample size: 20
Points of agreement
- Psychedelics like psilocybin and DMT act through 5-HT2A receptors to promote neuroplasticity, including dendritic spine formation and neurogenesis.
- Psilocybin shows promise as a therapeutic for depression and other psychiatric conditions, though evidence is still preliminary.
- Sex is an important biological variable influencing the effects of psychedelics, with females often showing stronger responses.
- Serotonergic signaling is implicated in the mechanisms of action of various treatments, including ketamine and ECT.
Conflicts
- Some studies report positive effects of psychedelics on social cognition, while others find limited direct evidence.
- Findings on the role of 5-HT2A antagonism in fear extinction are mixed, with one antagonist impairing extinction and others not.
- Safety profiles of psilocybin are debated, with some reviews suggesting low toxicity and others highlighting potential risks.
Gaps
- Long-term durability of psychedelic effects on neuroplasticity and clinical outcomes is not well established.
- Most studies are preclinical or in vitro; clinical evidence remains limited and often from small trials.
- Sex-specific effects are understudied, with many studies not reporting or analyzing sex differences.
- The relationship between acute serotonergic signaling and long-term structural plasticity is not fully understood.
- Safety data for psilocybin and other psychedelics in diverse populations are lacking.